A case is presented of a 41-year-old man with a history of recurrent renal stones over 10 years. Analysis of the stone showed that, although it gave a positive reaction with the non-speci c phosphotungstic acid test, uricase failed to identify any urate present. Analysis in a reference laboratory con rmed its composition as dihydroxyadenine. Patients who are homozygous for the rare autosomal-recessive adenine phosphoribosyltransferase de ciency, excrete large amounts of 2,8dihydroxyadenine, which has poor solubility at normal urinary pH. Treatment with the xanthine oxidase inhibitor allopurinol induces a total cessation of stone formation. Increased awareness of the condition and knowledge of the limitations of some methods of laboratory analysis for renal stones should help to identify this type of stone and prevent renal damage.
A 41-year-old man presented to his general practitioner with renal colic. He had su¡ered similar episodes over the previous 10 years and passed many stones. There was no positive family history. An intravenous urogram showed gross ureteric obstruction. The stone was radiolucent, suggesting it was composed of urate. The stone was removed ureteroscopically. A 24-h urine collection showed a urinary urate concentration of 4.3 mmol per 24 h (reference range 2.3-4.5). Serum urate (303 mmol/L) was within the reference range (5420 mmol/L).
Laboratory analysis of the stone gave a positive test for urate with the non-speci¢c reduction of phosphotungstic acid, but analysis with uricase failed to detect urate. The stone was sent for analysis by infrared spectroscopy and was shown to be composed mainly (92%) of 2,8-dihydroxyadenine (2,8-DHA). 1 Analysis of his red blood cells showed complete absence of the enzyme adenine phosphoribosyltransferase (APRT). 2 His father and two siblings all showed reduced levels of APRT (see Table 1 ).
The patient was treated with 300 mg of allopurinol daily. His urinary 2,8-DHA decreased from 0.106 mmol/ L at presentation to 0.063 mmol/ L. He has been stone-free for 5 years.
Discussion
2,8-DHA is the end-product of adenine oxidation by xanthine oxidase (see Fig. 1 ). Adenine is one of the chief purines in nucleic acids and nucleotides. It is biosynthesized in the body and not found in the diet. Uric acid is the ¢nal oxidation product (in man) of these purines. The adenine produced during purine metabolism is normally returned to the adenine monophosphate (AMP) pool by the salvage enzyme APRT. In the absence of this enzyme, excess adenine accumulates and is further metabolized by xanthine oxidase to 2,8-DHA (see Fig. 1 ). 3 De¢ciency of APRT is a rare autosomal-recessive disorder. 4 Homozygotes are totally de¢cient in the enzyme. Up to 1978, only three cases had been described in the literature, but awareness of the disorder has resulted in a further 47 cases being reported to date. At the pH of normal urine (5-7), 2,8- DHA is only sparingly soluble and there is a high risk of crystal and stone formation. Progression to renal insu¤ciency is a real risk. Heterozygote status is relatively common, occurring in 1% of the population. Heterozygotes show approximately 25% of normal APRT activity. They do not su¡er from recurrent stone disease as enzyme levels, although reduced, are adequate for adenine metabolism.
The de¢nitive diagnosis is made by measuring the enzyme APRT in a red cell haemolysate. Initially, three cases were diagnosed in children under 4 years of age. 5 At ¢rst these stones were reported to be composed of urate. However, true urate stones are yellowish and hard, whereas DHA stones are grey, friable and easily crushed. These children were treated by urine alkalinization and did not improve because DHA is poorly soluble at pH 7. Allopurinol is the treatment of choice since it prevents oxidation of adenine.
Conclusion
Several key lessons can be learnt from this case history. At the time of presentation this man had su¡ered from renal stones for 10 years. No previous stone had been sent for analysis. Previous radioimaging had reported no stones visible.
This case also illustrates the potential for misdiagnosis based on poor quality stone analysis in the laboratory. Wet methods for stone analysis will detect purine metabolites but the failure to react to uricase should alert analysts to the possibility that this is not a simple urate stone. Red cell DHA and APRT analysis will then con¢rm the diagnosis.
An awareness of the condition has led to a 16-fold increase in incidence over 20 years. Treatment with allopurinol will always cure these stones, as this case illustrates. 
